Novavax Inc (NAS:NVAX)

$ 8.75 0.245 (2.88%) Market Cap: 1.40 Bil Enterprise Value: 674.14 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 70/100

Q3 2024 Novavax Inc Earnings Call Transcript

Nov 12, 2024 / 01:30PM GMT

Release Date Price: $8.46 (-6.10%)

Transcript 10-Q8-K

Key Points

Positve

Novavax Inc (NVAX) has established a strategic partnership with Sanofi, which will lead to double-digit royalties from Sanofi's sales of the COVID-19 vaccine starting in 2025.
The company has made significant progress in reshaping itself into a leaner and more agile organization, with a 26% reduction in R&D and SG&A expenses compared to the previous year.
Novavax Inc (NVAX) has a strong cash position, ending the third quarter with over a billion in cash and accounts receivables.
The clinical hold on Novavax Inc (NVAX)'s COVID-19 influenza combination and standalone influenza vaccine candidates has been removed by the FDA, allowing them to proceed with phase three trials.
The company is leveraging its proven technology platform to drive additional partnerships and deals, with a focus on its Matrix-M adjuvant and nanoparticle protein-based technology.

Negative

Novavax Inc (NVAX)'s current market share of approximately 3% is trending below their full season expectations, leading to a revision of their full-year 2024 total revenue guidance.
The company faces challenges such as minimum purchase commitment contracts for mRNA vaccines and limited initial retail stocking of their vaccine.
There is uncertainty regarding the timing of the phase three trial start for their COVID-19 influenza combination vaccine due to recent clinical hold issues.
Novavax Inc (NVAX) has revised its full-year 2024 product sales guidance downward, primarily due to COVID-19 trends in the US market.
The company is actively exploring the sale of its Czech Republic manufacturing facility, indicating potential operational downsizing.

Operator

Good morning and welcome to Novavax's third quarter, 2024 financial results and operational highlights conference call. All participants will be in listen-only mode. Should you need assistance? Please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions to ask the questions. You may, you may press star followed by the one on your touchtone phone to withdraw your question. Please press star followed by the two. Please note this event is being recorded. I would now like to turn the conference over to Louis de Vice President, investor relations. Please go ahead.

Unidentified Company Representative

Good morning and thank you all for joining us today to discuss our third quarter, 2024 operational highlights and financial results.

A press release announcing our results is currently available on our website at Novavax dotcom and an audio archive of this conference call will be available on our website later today.

Please turn to slide 2.

Before we begin

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.